ISRCTN89801719已完成不适用
Estrogen Receptor Beta (ER-ß) as a predictor of endocrine therapy responsiveness ? A randomised neoadjuvant trial comparison between Anastrozole and Tamoxifen for the treatment of postmenopausal breast cancer
Federal University of Sao Paulo (Brazil)0 个研究点目标入组 90 人开始时间: 2013年2月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Histologically confirmed invasive breast cancer in women who were postmenopausal, which is defined as no menstruation periods over the last 12 months and/or an FSH level within the postmenopausal range.
排除标准
- •1. The presence of endocrine disease, metastatic disease, inflammatory breast cancer (T4d)
- •2. History of thromboembolism
- •3. Use of hormone replacement therapy (HRT) or previous treatment for breast cancer (surgery, radio or chemotherapy). Patients who do not comply with the prescribed medication regimen or postpone surgery are also excluded from the study. Patients who had previously taken HRT may be included if they have stopped hormonal treatment at least six months prior to trial randomisation.
研究者
相似试验
尚未招募
2 期
A study to check the outcomes of Triple Negative Breast Cancer patients with the presence of Estrogen receptor Beta and TP53 mutation and the outcomes of adding the drug Tamoxifen in these patients.CTRI/2023/09/057359AVNEET KAILASH AGRAWA
尚未招募
Unknown
Evaluating utility of Oestrogen and Progesterone Receptor biomarkers for prediction of colorectal CancerCTRI/2024/05/068054Datta Meghe Institute of Higher Education & Research (DMIHER)
尚未招募
不适用
presence of erbB receptors and estrogen receptors on the inner lining of the uterus during tumor of ovaryCTRI/2021/03/031825All India Institute of Medical Sciences
招募中
2 期
4FMFES-PET Imaging of ER+ Advanced Breast CancersER+ Breast CancerNCT04824014Centre de recherche du Centre hospitalier universitaire de Sherbrooke150
进行中（未招募）
2 期
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast CancerAdvanced Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaRecurrent Breast CarcinomaNCT03941730Mayo Clinic8